ESC 365 - Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial

ESC Premium Access

Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial

Session: Progress in secondary prevention - New treatments

Topic: Secondary Prevention

Speaker: Doctor T. Vanassche (Leuven, BE)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Thomas Vanassche

University Hospitals (UZ) Leuven, Leuven (Belgium)

2 presentations

0 follower

4 more presentations in this session

Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis

Speaker: Mr A. Roddick (Oxford, GB)

Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials

Speaker: Miss O. Ghosh-Swaby (London, CA)

Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy

Speaker: Professor M. Roe (Chapel Hill, US)

Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment

Speaker: Doctor R. Diaz (Rosario, AR)

Access the full session

Progress in secondary prevention - New treatments

Speakers: Doctor T. Vanassche, Mr A. Roddick, Miss O. Ghosh-Swaby, Professor M. Roe, Doctor R. Diaz

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources